Understanding biosimilars and projecting the cost savings to employers: Update

  • Print
  • Connect
  • Email
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
By Frank R. Kopenski, Katie Holcomb | 26 August 2015

Biosimilar market penetration will be highly dependent upon the physician, patient, and price while the pharmacy benefit manager and benefit design will also have an impact through formulary design and utilization management programs. This study quantifies the impact of biosimilar savings to employers and takes a close look at the potential drivers of cost savings and their variablity. Employers can use this study to help understand the implications of such changes on future healthcare expenditures and to understand the timing of these changes and how benefit design or pharmacy cost management will affect future cost savings.

This report was commissioned by AbbVie.

Authors